In colon cancer, GRPR enhances invasion through the RhoA/ROCK pathway [43], while in prostate cancer, GRPR overexpression promotes a malignant phenotype via activation of AKT1, PKCε, TYK2, and MST1 pathways [63]. Here, AKT1 is linked to prostate carcinoma.